Oyster Point Pharma Inc

Oyster Point Pharma — Investor Presentation (November 2020)

32 slides from Oyster Point Pharma's investor presentation, Nov 5, 2020

  1. Slide 1: Focused on Transformative Therapies for the Ocular Surface

    NASDAQ: OYST Focused on Transformative Therapies for the Ocular Surface Corporate Presentation November 2020 Exhibit 99.1

  2. Slide 2: Disclaimers and Forward-looking Statements

    Disclaimers and Forward-looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. (the “Company,” “we” or “our”) reg

  3. Slide 3: Treatment of Dry Eye Disease

    Treatment of Dry Eye Disease Dry Eye Disease Affects: ~34 MILLION ADULTS of all ages in the U.S. alone1 and >340 million worldwide2 ~16 MILLION ADULTS have been diagnosed, but < 2 million are currently on treatment ~7 MILLION ADULTS have tried current options Paulsen AJ, Cruickshanks KJ, Fischer ME,

  4. Slide 4: OC-01 Nasal Spray Highlights

    OC-01 Nasal Spray Highlights Novel mechanism of action to restore tear film homeostasis with natural tear production Rapid onset of action demonstrated in clinical trials to significantly improve signs and symptoms Improvement in tear production demonstrated in the majority of a broad population of

  5. Slide 5: OC-01 Targets Re-Establishing Tear Film Homeostasis

    OC-01 Targets Re-Establishing Tear Film Homeostasis Dry Eye

  6. Slide 6: OC-01 Breaks the Cycle Progression of Dry Eye Disease

    OC-01 Breaks the Cycle Progression of Dry Eye Disease by Re-Establishing Natural Tear Film Production Dry Eye

  7. Slide 7: There is No Substitute for Natural Tear Film

    There is No Substitute for Natural Tear Film Natural tears contain a complex mixture of lipids, proteins, mucins, and electrolytes Over 1,500 proteins 5+ lipid classes 20+ mucins Growth factors, such as nerve growth factor (NGF) and epidermal growth factor (EGF), found in natural human tears, are cr

  8. Slide 8: Tear Film is Produced by the Lacrimal Functional Unit

    Tear Film is Produced by the Lacrimal Functional Unit LACRIMAL GLANDS Produce the aqueous which contains proteins, enzymes, antibodies and growth factors that are cytoprotective, anti-inflammatory, and anti-microbial. MEIBOMIAN GLANDS Produce the lipid layer which reduces evaporation and promotes te

  9. Slide 9: OC-01's Nasal Delivery is Critical to the Novel MOA

    OC-01’s Nasal Delivery is Critical to the Novel MOA The trigeminal nerve is accessible within the nasal cavity, activated by OC-01 by stimulating cholinergic receptors The trigeminal nerve provides the pathway for parasympathetic stimulation of the Lacrimal Functional Unit (LFU) to promote complete

  10. Slide 10: OC-01 (varenicline) Nasal Spray is a Selective Cholinergic Agonist

    OC-01 (varenicline) Nasal Spray is a Selective Cholinergic Agonist Preservative-free nasal spray, containing the selective cholinergic agonist, varenicline. Binds to receptors located on the trigeminal nerve, readily accessible within anterior portion of the nasal cavity, to open ion channels and de

  11. Slide 11: ONSET-1 Phase 2b Study Design

    Multicenter, Randomized, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of OC-01 Nasal Spray on the Signs and Symptoms of Dry Eye Disease ONSET-1 Phase 2b Study Design Primary (Sign) Endpoint: Secondary (Symptom) Endpoints: Schirmer’s Score at Week 4 (Day 28) Vi

  12. Slide 12: ONSET-2 Phase 3 Study Design

    Diagnosed Dry Eye Disease Schirmer’s Score ≤ 10 mm *OSDI ≥ 23 EDS 0-100 N=758 n=246 n=260 n=252 1.2 mg/ml OC-01 Nasal Spray 0.6 mg/ml OC-01 Nasal Spray Vehicle Control (Placebo) Randomized 1:1:1 BID for 28 Days Primary (Sign) Endpoint: Secondary (Symptom) Endpoints: Categorical Schirmer’s Score at W

  13. Slide 13: Improvement in Signs of Dry Eye Disease: Schirmer's Responders

    ITT-population Cochran-Mantel-Haenszel (CMH) test controlling for study site, baseline STS and baseline EDS All comparisons made to control group. Missing data were imputed using last-available data. * Nominal p-value 0.6 mg/ml 1.2 mg/ml n=43 n=48 n=44 Control 0.6 mg/ml 1.2 mg/ml n=252 n=260 n=246 p

  14. Slide 14: Improvement in Signs: Mean Change in Schirmer's Score

    0.6 mg/ml 1.2 mg/ml n=43 n=46 n=40 0.6 mg/ml n=248 n=251 n=235 p<0.0001* p<0.0001* p<0.001 p<0.001 Control 0.6 mg/ml 1.2 mg/ml ITT-population. Least Square (LS) means were derived from ANCOVA model with treatment, site, baseline STS and baseline EDS as covariates. Missing data were imputed using las

  15. Slide 15: MYSTIC Sustained Improvement in Signs

    Mean Change in Schirmer’s Score (mm) Intent To Treat - Observed Mean Change from Baseline n=33 n=35 n=31 n=31 n=34 n=31 n=31 n=35 n=30 n=35 n=29 n=32 MYSTIC Sustained Improvement in Signs Mean Change from Baseline in Schirmer’s Score (mm) - Week 12 Week 12

  16. Slide 16: Improvement in Symptoms in Controlled Adverse Environment

    Control Control 0.6 mg/ml 0.6 mg/ml 1.2 mg/ml 1.2 mg/ml N=38 N=45 N=42 N=171 N=187 N=169 p=0.001 ITT-population, Least Square (LS) means were derived from ANCOVA model with baseline, site, and treatment group as covariates. All comparisons made to control group ITT-population (excluding sites 45 and

  17. Slide 17: Improvement in Symptoms: Eye Dryness Score Week 4

    Control Control 0.6 mg/ml 0.6 mg/ml 1.2 mg/ml 1.2 mg/ml N=40 N=46 N=43 N=242 N=255 N=248 p=0.01 p=0.07 T population, Least Square (LS) means were derived from ANCOVA model with treatment, site, baseline STS and baseline EDS as covariates. Missing data were imputed using last-available data . All com

  18. Slide 18: Improvement in Symptoms: Eye Dryness Score Weeks 1, 2, 4

    Improvement in Symptoms Mean Change in Baseline Eye Dryness Score- Week 1, 2, 4 Data Presented with imputation for missing assessments P<0.001 EDS Score (mm) ITT-population, Least Square (LS) means were derived from ANCOVA model with treatment, site, baseline STS, and baseline EDS as covariates. All

  19. Slide 19: ONSET-1 Safety: Adverse Events

    Adverse Events Potentially Related to OC-01 Nasal Spray Administration Events in >5% of Subjects OC-01 0.12 mg / mL (n=47) OC-01 0.6 mg / mL (n=48) OC-01 1.2 mg / mL (n=44) Control Sneeze after any installation 29 (62%) 38 (79%) 37 (84%) 0 Cough after any instillation 4 (9%) 6 (13%) 11 (25%) 0 Throa

  20. Slide 20: ONSET-2 Safety: Adverse Events

    Adverse Events Potentially Related to OC-01 Nasal Spray Administration Events in >5% of Subjects ONSET-2 Safety Control (n=251) OC-01 0.6 mg / mL (n=260) OC-01 1.2 mg / mL (n=245) Total (n=756) Sneeze after any installation 73 (29.1%) 247 (95.0%) 237 (96.7%) 557 (73.7%) Cough after any instillation

  21. Slide 21: Integrated ONSET-1 / ONSET-2 Sign & Symptom Comparison

    Integrated ONSET-1 / ONSET-2 Study Sign & Symptom Comparison Symptom benefit in 1.2 mg/ml Dose Group vs. 0.6 mg/ml Dose Group Endpointa OC‑01 0.6 mg/mL OC‑01 1.2 mg/mL Schirmer’s Test Score (STS), Subjects with ≥10 mm Improvement Odds Ratio (95% CI) p‑valuea STS, Week 4, Study Eye (Obs)b 2.84 (1.901

  22. Slide 22: Next Steps for OC-01 (varenicline) Nasal Spray

    Next Steps for OC-01 (varenicline) Nasal Spray OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease Remains on Track for Q4 2020 Planned U.S. launch of OC-01 in Q4 2021, if FDA-approved 1.2 mg/ml Dose Favored Based on Sympto

  23. Slide 23: Neurotrophic Keratitis

    Neurotrophic Keratitis Neurotrophic Keratitis Disease Causes Pathophysiology NK is a rare, degenerative disease resulting from a loss of corneal sensation, which causes progressive damage to the cornea Herpes simplex, varicella zoster (shingles), diabetes, multiple sclerosis, leprosy Corneal hypoest

  24. Slide 24: OLYMPIA Phase 2 Study Design

    Diagnosed Neurotrophic Keratitis Mackie Classification: Stage 1 (corneal epithelial hyperplasia / punctate keratopathy) Stage 2 (persistent epithelial defect) N=200 n=100 n=100 1.2 mg/ml OC-01 Nasal Spray Vehicle Control (Placebo) Randomized 1:1 BID for 56 Days Phase 2 Multicenter, Randomized, Contr

  25. Slide 25: Strong Global IP Position

    Strong Global IP Position U.S. license granted for varenicline tartrate by Pfizer Five issued U.S. patents (expiration as early as 2035) relating to methods and/or formulations Patents relating to methods of treating dry eye disease, increasing tear production, and improving ocular discomfort using

  26. Slide 26: Patients and Doctors Need Additional Options

    Patients and Doctors Need Additional Options OF EYE DOCTORS state they can adequately treat dry eye patients with current options1. 10% 1 2018 ZS Market Research ECP (n= 451) and Patient (n=146) ONLY

  27. Slide 27: Estimated ~13M Adults May Be Amenable to a New Treatment

    An Estimated ~13M Adults May Be Amenable to a New Treatment, Out of the ~16M Diagnosed DED Adults in the U.S. ~13M diagnosed patients that are willing to try new treatments of patients ever treated with Rx are willing to try a new treatment Potential Addressable DED Population 7M PATIENTS 2M PATIENT

  28. Slide 28: Competitively Sized Sales Force

    Competitively Sized Sales Force of 150 to 200 People Source: IQVIA Xponent PlanTrak Data Dry Eye Disease (DED) Market limited to Restasis®, Restasis MultiDose®, Xiidra® and Cequa™. Date: 8.2018 – 7.2020 Concentration of Dry Eye Treaters (IQVIA Xponent PlanTrak 2020) Approximately 34K ECPs have presc

  29. Slide 29: Dry Eye Disease Market Access Landscape

    Dry Eye Disease Market Access Landscape Payor Management Formulary Considerations Payors view Dry Eye Disease as a low to moderate priority for management Coverage will depend on well-differentiated clinical profile and net cost Commercial: 50% of the DED TRx market Formulary reviews and decisions i

  30. Slide 30: Preparing for Launch of OC-01 Nasal Spray

    Preparing for Launch of OC-01 Nasal Spray We are focused on addressing the unmet needs of a broad audience: The mild, moderate, and severe Dry Eye patient The Eye Care Professionals (ECPs), ophthalmologists and optometrists, that take care of them We plan to enable patient access to OC-01 nasal spra

  31. Slide 31: Financial Highlights

    Financial Highlights First Follow-on Offering (5/2020): Initial Public Offering (11/2019): $92M gross proceeds 5.75M shares @ $16 per share $121M gross proceeds 4.31M shares @ $28 per share Balance Sheet (9/30/20): Income Statement (9/30/20):

  32. Slide 32: ‘\OYSTER === =

    ‘\OYSTER === = © POINT ; » NASDAQ. OYST

Oyster Point Pharma — Investor Presentation (November 2020) on 6ix